Atay Oguzhan sold $2.6M of BLLN

Atay Oguzhan (See Remarks) sold 26,250 shares of BillionToOne, Inc. (BLLN) at an average of $97.66 ($94.76–$100.87, $2.56M total) across 8 trades on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Jun 11, 2026, 12:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosure provides a fresh, timestamped data point on insider selling activity (size, date, and price range) but does not introduce new operational, financial, or regulatory developments.

02

Market read

Useful for monitoring insider behavior and potential sentiment drift, but not a standalone fundamental catalyst.

03

What to watch

Traders may over-weight insider sales; the filing lacks any accompanying explanation, and the transaction occurred across multiple trades on a single day.

Relevance 5/10Novelty 8/10Timing: SEC Form 4 filed June 10 (covering June 8 sales)

Background

The article reports an SEC Form 4 insider transaction for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

Officer/director Atay Oguzhan sold $2.56M of BillionToOne shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Modest, short-lived negative-to-neutral sentiment impact possible; no clear directional fundamental catalyst from the filing alone.

Evidence & confidence

The article is a primary-source insider transaction with explicit 10b5-1 pre-arrangement and the filing provides sale size/price range but no new company operating or guidance information.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/operational trigger.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • BillionToOne, Inc.

    Subject of the SEC Form 4 insider sale disclosed in the article.

  • Atay Oguzhan

    Officer/director who sold shares; transaction is open-market and under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.